Company intelligence / Profile preview

Sommetrics

San Diego / Vista, California, United Statessommetrics.com ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Interim data from the pivotal SUPRA study and eight earlier studies show that the aerSleep II device achieves clinically meaningful reductions in apnea-hypopnea index in over 70% of patients with all levels of disease. The device has demonstrated a favorable safety profile and high patient preference compared to previous treatments. All subjects have exceeded Medicare compliance criteria after six months of home use. Earlier versions received Health Canada clearance and FDA Breakthrough Device designation

Therapeutic areas: Pulmonology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

None disclosed; no major pharma/biotech partnerships publicly listed.

Beyond the preview

Go deeper on Sommetrics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sommetrics.

Explore the full profile